Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for metastatic prostate cancer

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1561-1568

  O’Donnell, Robert T ^a   DeNardo, Sally J ^a   Yuan, Aina ^a   Shen, Sui ^a   Richman, Carol M ^a   Lara, Primo N ^a   Griffith, Irwin J ^a,b   Goldstein, Desiree S ^a   Kukis, David L ^a   Martinez, Gerard S ^a   Mirick, Gary R ^a   DeNardo, Gerald L ^a   Meyers, Frederick J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (BROMOACETAMIDO)BENZYL] 1,4,7,10 TETRAAZACYCLODECANE N,N',N''',N'''' TETRAACETIC ACID; 2 IMINOTHIOLANE; 2 IMINOTHIOLANE 2 [4 (BROMOACETAMIDO)BENZYL] 1,4,7,10 TETRAAZACYCLODECANE N,N',N''',N'''' TETRAACETIC ACID MONOCLONAL ANTIBODY M170 Y 90; 2 IMINOTHIOLANE 2 [4 (BROMOACETAMIDO)BENZYL] 1,4,7,10 TETRAAZACYCLODECANE N.N'.N''',N'''' TETRAACETIC ACID MONOCLONAL ANTIBODY M170 IN 111; CAPROMAB PENDETIDE IN 111; CHELATING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M170; PROSTATE SPECIFIC ANTIGEN; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION;

ADENOCARCINOMA; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; INDIUM RADIOISOTOPES; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; TIME FACTORS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 0034895678     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cancer Statistics 2000
2. Goserelin acetate and flutamide versus bilateral orchiectomy: A Phase III EORTC trial (30853)
3. Molecular biology of prostate carcinogenesis
4. A revolution in the treatment of non-Hodgkin's lymphoma
5. Development of monoclonal antibody imaging of metastatic prostatic carcinoma
6. Current status of monoclonal antibodies for imaging and therapy of prostate cancer
7. Treatment of hormone-refractory prostate cancer with 90-Y-CYT-356 monoclonal antibody
8. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49
9. Treatment of refractory prostate carcinoma with 90Y KC4
10. 111In
11. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study
12. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane
13. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates
14. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity, and tumor regression in patients with lymphoma
15. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a Phase I clinical trial
16. Antibody responses to macrocycles in lymphoma
17. 131I-Lym-1 in patients with B-cell malignancies
18. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy
19. Dosimetric evaluation of Copper-64 in Copper-67-2IT-BAT-Lym-1 for radioimmunotherapy
20. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma
21. 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study
22. Prediction of myelotoxicity using radiation doses to marrow from body, blood, and marrow sources
23. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation, part 2
24. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts
25. The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids
26. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic chelating agent
27. 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A
28. Indium-111 Capromab Pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer
29. Clinical applications of radioimmunoscintigraphy with prostate-specific antibodies for prostate cancer
30. 131I-labeled CC49; outcomes in patients with androgen- independent prostate cancer
31. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody
32. High-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous hematopoietic stem cell support (AHSCS) in patients with metastatic breast cancer
33. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49
34. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid carcinoma using 131-I-MN-14 F(ab)2 anticarcinoembryonic antigen (CEA) monoclonal antibody and autologous hematopoietic stem rescue (AHSCR)